Journal of Prevention and Treatment for Stomatological Diseases ›› 2019, Vol. 27 ›› Issue (12): 809-812.DOI: 10.12016/j.issn.2096-1456.2019.12.012

• Review Articles • Previous Articles     Next Articles

Research progress on the role and mechanism of miR-155 in the development of oral squamous cell carcinoma

HUANG Lihuan,JIANG Yingtong,OUYANG Kexiong,WU Lihong(),YANG Xuechao()   

  1. Affiliated Stomatological Hospital of Guangzhou Medical University·Guangzhou Institute of Oral Diseases·Key Laboratory of Stomatology, Guangzhou 510140, China
  • Received:2018-10-25 Revised:2019-06-13 Online:2019-12-20 Published:2019-12-30
  • Contact: Lihong WU,Xuechao YANG



  1. 广州医科大学附属口腔医院·广州口腔疾病研究所·口腔医学重点实验室,广东 广州(510140)
  • 通讯作者: 吴丽红,杨雪超
  • 作者简介:黄丽环,本科生在读,Email:;|江颖彤,硕士研究生在读,Email:,共同第一作者
  • 基金资助:


Oral squamous cell carcinoma (OSCC) is the most common oral cancer. Previous studies have found significantly high miR-155 expression in OSCC. However, the mechanism by which miR-155 plays a role in OSCC oncogenesis is not yet clear. This article reviews the function of the relationship between miR-155 and tumors and the potential role of miR-155 in the development of OSCC. A literature review showed that mir-155, as a small carcinogenic RNA, can inhibit CDC73, BCL6, P27Kip1 and other target genes that play a role in cancer inhibition; promote the proliferation, migration and invasion of OSCC cells; and inhibit apoptosis. miR-155 can also be combined with biological factors (Epstein-Barr virus, human papillomavirus) to promote the development of OSCC.

Key words: oral squamous cell carcinoma, oncogene, microRNA, miR-155, epstein-barr virus(EBV), human papillomavirus(HPV), target gene, biomarker


口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC),是口腔中最常见的癌症。研究表明,miR-155在OSCC中呈现高表达,而目前miR-155 在 OSCC 发生的作用与机制尚未明确,本文拟讨论miR-155与肿瘤的关系及其在OSCC发生发展中可能起到的作用。文献复习结果表明 miR-155作为致癌性的小RNA可抑制CDC73、BCL6、P27Kip1等具有抑癌作用的靶基因,促进OSCC细胞的增殖、迁移和侵袭行为,抑制细胞凋亡;还可与生物因素(EB病毒、人乳头瘤病毒)共同作用促进OSCC的发生。

关键词: 口腔鳞状细胞癌, 癌基因, micro RNA, miR-155, EB病毒, 人乳头瘤病毒, 靶基因, 生物标志物

CLC Number: